Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
Zymeworks completes its Theravance Biopharma acquisition, boosts 2026 revenue guidance, and gains recurring revenue from YUPELRI sales.
Stocks · News reference
Citigroup Maintains Buy on Zymeworks, Raises Price Target to $39
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
Zymeworks completed its acquisition of Theravance Biopharma, adding YUPELRI to its portfolio and providing durable cash flows. The company updated 2026 guidance to $278-292 million in total revenue and $114-128 million in Adjusted EBITDA. The acquisition is expected to deliver mid-teens IRR with immediate accretive revenue and cash flow, financed through a $350 million non-recourse note from OMERS and $217.5 million in existing cash.
Zymeworks Sees FY2026 Sales $278.000M-$292.000M vs $302.577M Est
Zymeworks (NASDAQ:ZYME) sees FY2026 sales of $278.000 million-$292.000 million vs $302.577 million analyst estimate.